Horizon Investments LLC Invests $658,000 in Omnicell, Inc. $OMCL

Horizon Investments LLC acquired a new position in Omnicell, Inc. (NASDAQ:OMCL) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 14,532 shares of the company’s stock, valued at approximately $658,000.

Several other large investors have also recently bought and sold shares of OMCL. Millennium Management LLC acquired a new position in Omnicell during the 3rd quarter valued at $25,625,000. Two Sigma Investments LP grew its holdings in shares of Omnicell by 93.8% in the 3rd quarter. Two Sigma Investments LP now owns 559,969 shares of the company’s stock worth $17,051,000 after purchasing an additional 271,008 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Omnicell by 9.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,364,068 shares of the company’s stock worth $71,985,000 after purchasing an additional 197,462 shares during the last quarter. Qube Research & Technologies Ltd grew its holdings in Omnicell by 38.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 653,971 shares of the company’s stock worth $19,227,000 after acquiring an additional 181,394 shares during the last quarter. Finally, UBS Group AG grew its holdings in Omnicell by 145.0% during the 3rd quarter. UBS Group AG now owns 276,286 shares of the company’s stock worth $8,413,000 after acquiring an additional 163,499 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Omnicell Price Performance

NASDAQ:OMCL opened at $43.82 on Friday. The firm has a fifty day simple moving average of $37.38 and a 200 day simple moving average of $39.87. Omnicell, Inc. has a 1-year low of $25.44 and a 1-year high of $55.00. The stock has a market capitalization of $1.99 billion, a PE ratio of 99.59, a P/E/G ratio of 1.09 and a beta of 0.96. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings results on Tuesday, April 28th. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The business had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. During the same quarter last year, the firm posted $0.26 EPS. The company’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. On average, research analysts expect that Omnicell, Inc. will post 1.34 EPS for the current fiscal year.

Insider Buying and Selling at Omnicell

In other news, EVP Corey J. Manley sold 7,405 shares of Omnicell stock in a transaction on Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the sale, the executive vice president owned 96,717 shares of the company’s stock, valued at approximately $3,355,112.73. This trade represents a 7.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 2.92% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Piper Sandler reissued an “overweight” rating and set a $49.00 price objective (down from $63.00) on shares of Omnicell in a report on Friday, February 6th. Wells Fargo & Company increased their price target on shares of Omnicell from $52.00 to $55.00 and gave the company an “overweight” rating in a research report on Thursday, April 23rd. Bank of America raised Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research note on Wednesday, February 4th. KeyCorp increased their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 28th. Finally, UBS Group set a $60.00 price target on shares of Omnicell and gave the stock a “buy” rating in a research note on Friday, March 13th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat, Omnicell currently has an average rating of “Buy” and an average target price of $59.86.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.